{"id":5756,"date":"2021-12-06T06:41:19","date_gmt":"2021-12-06T06:41:19","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=5756"},"modified":"2023-09-25T13:54:24","modified_gmt":"2023-09-25T13:54:24","slug":"maat-pharma-annonce-lexercice-partiel-de-loption-de-surallocation-et-le-montant-definitif-de-loffre-porte-a-environ-357-me","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-annonce-lexercice-partiel-de-loption-de-surallocation-et-le-montant-definitif-de-loffre-porte-a-environ-357-me\/","title":{"rendered":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h6 style=\"text-align: center;\">Communication \u00e0 caract\u00e8re promotionnel<br \/>\n<em>Ce communiqu\u00e9 ne peut \u00eatre distribu\u00e9 directement ou indirectement<br \/>\naux Etats-Unis d\u2019Am\u00e9rique, au Canada, en Australie, au Japon ou en Afrique du Sud.<\/em><\/h6>\n[\/vc_column_text][image_with_animation image_url=\u00a0\u00bb4333&Prime; animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][vc_column_text]\n<h3 style=\"text-align: center;\"><strong>MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac<\/strong><\/h3>\n[\/vc_column_text]<div class=\"nectar-fancy-ul\" data-list-icon=\"icon-salient-thin-line\" data-animation=\"false\" data-animation-delay=\"0\" data-color=\"accent-color\" data-spacing=\"default\" data-alignment=\"left\"> \n<ul>\n<li>Exercice partiel de l\u2019option de surallocation \u00e0 hauteur de 314 055 actions nouvelles soit environ 4,2 M\u20ac<\/li>\n<li>Montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac<\/li>\n<\/ul>\n <\/div>[vc_column_text]<strong>MaaT Pharma S.A. (<\/strong>\u00ab <strong>MaaT Pharma <\/strong>\u00bb<strong> ou la <\/strong>\u00ab <strong>Soci\u00e9t\u00e9 <\/strong>\u00bb<strong>), soci\u00e9t\u00e9 fran\u00e7aise de biotechnologies en stade clinique avanc\u00e9, pionni\u00e8re dans le d\u00e9veloppement de m\u00e9dicaments dans la restauration du microbiote<a href=\"#_ftn1\" name=\"_ftnref1\"><sup>[1]<\/sup><\/a> intestinal pour am\u00e9liorer la survie des patients atteints de cancers, <\/strong>annonce aujourd\u2019hui l\u2019exercice partiel de l\u2019option de surallocation dans le cadre de son introduction en bourse sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext \u00e0 Paris (code ISIN : FR0012634822 &#8211; mn\u00e9monique : MAAT).<\/p>\n<p>Le 3 d\u00e9cembre 2021, Portzamparc BNP Paribas, agissant en qualit\u00e9 d\u2019agent stabilisateur et de Coordinateur Global, Chef de File et Teneur de Livre Associ\u00e9, a exerc\u00e9 partiellement l\u2019option de surallocation, donnant lieu \u00e0 l\u2019\u00e9mission de 314 055 actions nouvelles suppl\u00e9mentaires (sur un maximum de 349.999 actions) pour un montant total d&rsquo;environ 4,2 millions d\u2019euros, au prix de l\u2019offre, soit 13,50 euros par action.<\/p>\n<p>En cons\u00e9quence, le nombre total d\u2019actions MaaT Pharma offertes dans le cadre de son introduction en bourse s\u2019\u00e9l\u00e8vera \u00e0 2 647 388 actions, portant ainsi la taille de l\u2019offre \u00e0 environ 35,7 millions d\u2019euros \u00e0 l\u2019issue du r\u00e8glement-livraison des actions nouvelles suppl\u00e9mentaires pr\u00e9vu le 7 d\u00e9cembre 2021.<\/p>\n<p>\u00c0 l&rsquo;issue de ces op\u00e9rations, le capital social de MaaT Pharma sera compos\u00e9 de 9\u00a0828 835 actions.<\/p>\n<p>Par ailleurs, conform\u00e9ment aux dispositions du R\u00e8glement (UE) n\u00b0596\/2014 du Parlement europ\u00e9en et du Conseil du 16 avril 2014 sur les abus de march\u00e9 et \u00e0 l\u2019article 6 du r\u00e8glement d\u00e9l\u00e9gu\u00e9 UE 2016\/1052 du 8 mars 2016 concernant les conditions applicables aux programmes de rachat d\u2019actions et aux mesures de stabilisation, Portzamparc BNP Paribas, en sa qualit\u00e9 d\u2019agent stabilisateur, indique qu\u2019il a r\u00e9alis\u00e9 des op\u00e9rations de stabilisation sur les actions MaaT Pharma comme suit :<\/p>\n<p>La stabilisation a d\u00e9but\u00e9 le 8 novembre 2021 et s\u2019est achev\u00e9e le 3 d\u00e9cembre 2021. La derni\u00e8re op\u00e9ration de stabilisation a \u00e9t\u00e9 effectu\u00e9e le 3 d\u00e9cembre 2021. Les op\u00e9rations de stabilisation ont \u00e9t\u00e9 r\u00e9alis\u00e9es dans les conditions suivantes :<\/p>\n<table width=\"550\">\n<tbody>\n<tr>\n<td width=\"80\"><strong>Date d\u2019interventions<\/strong><\/td>\n<td width=\"73\"><strong>Interm\u00e9diaire<\/strong><\/td>\n<td width=\"49\"><strong>Achat \/ Vente \/ transfert<\/strong><\/td>\n<td width=\"51\"><strong>Nombre d\u2019actions<\/strong><\/td>\n<td width=\"75\"><strong>Prix moyen de la transaction (en euros)<\/strong><\/td>\n<td width=\"65\"><strong>Prix bas \/ prix haut (en euros)<\/strong><\/td>\n<td width=\"80\"><strong>Montant total (en euros)<\/strong><\/td>\n<td width=\"76\"><strong>March\u00e9 <\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"80\">08\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">6 453<\/td>\n<td width=\"75\">13,5<\/td>\n<td width=\"65\">13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 87 115,50<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">09\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">250<\/td>\n<td width=\"75\">13,5<\/td>\n<td width=\"65\">13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 3 375,00<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">10\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">820<\/td>\n<td width=\"75\">13,5<\/td>\n<td width=\"65\">13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 11 070,00<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">11\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">1 111<\/td>\n<td width=\"75\">13,5<\/td>\n<td width=\"65\">13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 14 998,50<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">12\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">2 520<\/td>\n<td width=\"75\">13,5<\/td>\n<td width=\"65\">13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 34 020,00<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">15\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">5 050<\/td>\n<td width=\"75\">13,3812<\/td>\n<td width=\"65\">13,3 \/ 13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 67 575,06<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">16\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">904<\/td>\n<td width=\"75\">13,3272<\/td>\n<td width=\"65\">13,2 \/ 13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 12 047,79<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">17\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">1 550<\/td>\n<td width=\"75\">13,0388<\/td>\n<td width=\"65\">12,6 \/ 13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 20 210,14<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">18\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">2 722<\/td>\n<td width=\"75\">13,1242<\/td>\n<td width=\"65\">12,7 \/13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 35 724,07<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">19\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">295<\/td>\n<td width=\"75\">13,4486<\/td>\n<td width=\"65\">13,4 \/ 13,5<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 3 967,34<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">22\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">0<\/td>\n<td width=\"75\"><\/td>\n<td width=\"65\"><\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 &#8211;<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">23\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">208<\/td>\n<td width=\"75\">13,3885<\/td>\n<td width=\"65\">13,35 \/ 13,45<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 2 784,81<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">24\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">90<\/td>\n<td width=\"75\">13,3222<\/td>\n<td width=\"65\">13,1 \/ 13,4<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 1 199,00<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">25\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">340<\/td>\n<td width=\"75\">13,2824<\/td>\n<td width=\"65\">13,1 \/ 13,3<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 4 516,02<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">26\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">582<\/td>\n<td width=\"75\">12,9768<\/td>\n<td width=\"65\">12,85 \/ 13,2<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 7 552,50<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">29\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">725<\/td>\n<td width=\"75\">12,413<\/td>\n<td width=\"65\">12,3 \/ 12,8<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 8 999,43<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">30\/11\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">2381<\/td>\n<td width=\"75\">11,9515<\/td>\n<td width=\"65\">11,3 \/ 12,8<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0 28 456,52<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">01\/12\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">513<\/td>\n<td width=\"75\">12,9397<\/td>\n<td width=\"65\">12,85 \/ 12,95<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 6 638,07<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">02\/12\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">200<\/td>\n<td width=\"75\">12,77<\/td>\n<td width=\"65\">12,6 \/ 13<\/td>\n<td width=\"80\">\u00a0\u00a0\u00a0\u00a0\u00a0 2 554,00<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<tr>\n<td width=\"80\">03\/12\/2021<\/td>\n<td width=\"73\">Portzamparc<\/td>\n<td width=\"49\">Achat<\/td>\n<td width=\"51\">9230<\/td>\n<td width=\"75\">13,2248<\/td>\n<td width=\"65\">12,8 \/ 13,5<\/td>\n<td width=\"80\">\u00a0 122 064,90<\/td>\n<td width=\"76\">Euronext Paris<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p><strong>R\u00e9partition du capital <\/strong><\/p>\n<p>A l&rsquo;issue de l&rsquo;introduction en bourse et de l\u2019exercice partiel de l\u2019option de surallocation, la r\u00e9partition du capital et des droits de vote de la Soci\u00e9t\u00e9 est, \u00e0 la connaissance de la Soci\u00e9t\u00e9, la suivante :<\/p>\n<p>&nbsp;<\/p>\n<table width=\"644\">\n<tbody>\n<tr>\n<td width=\"217\"><strong>\u00a0<\/strong><\/td>\n<td colspan=\"2\" width=\"427\"><strong>Apr\u00e8s l&rsquo;exercice de l&rsquo;option de surallocation<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"217\"><strong>Actionnaires<\/strong><\/td>\n<td width=\"213\"><strong>Nombre d&rsquo;actions<\/strong><\/td>\n<td width=\"213\"><strong>% du capital social et des droits de vote<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Herv\u00e9 Affagard<\/td>\n<td width=\"213\">133 848<\/td>\n<td width=\"213\">1,36%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\"><strong>Total Mandataires sociaux personnes physiques<\/strong><\/td>\n<td width=\"213\"><strong>133 848<\/strong><\/td>\n<td width=\"213\"><strong>1,36%<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Fonds Seventure<\/td>\n<td width=\"213\">2 345 236<\/td>\n<td width=\"213\">23,86%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Cr\u00e9dit Mutuel Innovation SAS<\/td>\n<td width=\"213\">1 412 364<\/td>\n<td width=\"213\">14,37%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Biocodex SAS<\/td>\n<td width=\"213\">977 905<\/td>\n<td width=\"213\">9,95%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Symbiosis LLC<\/td>\n<td width=\"213\">2 027 702<\/td>\n<td width=\"213\">20,63%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">FPCI Fonds PSIM<\/td>\n<td width=\"213\">1 177 439<\/td>\n<td width=\"213\">11,98%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Autres Investisseurs<\/td>\n<td width=\"213\">368 883<\/td>\n<td width=\"213\">3,75%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\"><strong>Total actionnaires historiques<\/strong><\/td>\n<td width=\"213\"><strong>8 309 529<\/strong><\/td>\n<td width=\"213\"><strong>84,54%<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Salari\u00e9s et consultants<\/td>\n<td width=\"213\">248 838<\/td>\n<td width=\"213\">2,53%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Auto-d\u00e9tention<\/td>\n<td width=\"213\">0<\/td>\n<td width=\"213\">0,00%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\">Public<\/td>\n<td width=\"213\">1 136 620<\/td>\n<td width=\"213\">11,56%<\/td>\n<\/tr>\n<tr>\n<td width=\"217\"><strong>TOTAL<\/strong><\/td>\n<td width=\"213\"><strong>9 828 835<\/strong><\/td>\n<td width=\"213\"><strong>100,00%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u00a0<\/strong><\/p>\n<table width=\"100%\">\n<tbody>\n<tr>\n<td>Long-term<\/p>\n<p>Expansion<\/p>\n<p>(Immune \/<\/p>\n<p>inflammatory)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Mise \u00e0 disposition du Prospectus<\/strong><\/p>\n<p>Le document d&rsquo;enregistrement de la Soci\u00e9t\u00e9 approuv\u00e9 par l&rsquo;AMF en date du 1<sup>er<\/sup> octobre 2021 sous le num\u00e9ro I.21-057, le suppl\u00e9ment au document d&rsquo;enregistrement approuv\u00e9 par l&rsquo;AMF en date du 14 octobre 2021 sous le num\u00e9ro I.21-061, la note d&rsquo;op\u00e9ration et le r\u00e9sum\u00e9 du prospectus sont disponibles sans frais et sur simple demande aupr\u00e8s de MaaT Pharma et sur les sites Internet : <a href=\"http:\/\/www.amf-france.org\/\">www.amf-france.org<\/a> et <a href=\"http:\/\/investir.maatpharma.com\">investir.maatpharma.com<\/a>. L&rsquo;approbation du Prospectus ne doit pas \u00eatre consid\u00e9r\u00e9e comme un avis favorable sur les valeurs mobili\u00e8res offertes ou admises \u00e0 la n\u00e9gociation sur le march\u00e9 r\u00e9glement\u00e9 d\u2019Euronext Paris.<\/p>\n<h6><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Le microbiote intestinal (aussi appel\u00e9 \u00ab\u00a0flore intestinale\u00a0\u00bb)\u00a0d\u00e9signe l\u2019ensemble des micro-organismes (bact\u00e9ries, arch\u00e9es, levures, virus\u2026) naturellement pr\u00e9sents dans l\u2019intestin. Il joue notamment un r\u00f4le important dans l\u2019\u00e9ducation et la modulation du syst\u00e8me immunitaire et dans le m\u00e9tabolisme.<\/h6>\n[\/vc_column_text][vc_column_text]<strong>A propos de MaaT Pharma<\/strong><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologies au stade clinique qui a mis au point une approche compl\u00e8te pour restaurer la symbiose microbiote\/h\u00f4te des patients atteints de cancers. Engag\u00e9e dans le traitement des cancers et de la maladie du greffon contre l\u2019h\u00f4te (GVH), une complication grave survenant apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques, MaaT Pharma a d\u00e9j\u00e0 r\u00e9alis\u00e9 la preuve de concept de son approche chez des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb et dans un essai clinique de Phase 2 dans la GVH aigu\u00eb. Pour soutenir le d\u00e9veloppement de son portefeuille de produits et son extension \u00e0 des indications plus larges, MaaT Pharma a d\u00e9velopp\u00e9 gutPrint\u00ae, une puissante plateforme de d\u00e9couverte et d\u2019analyse pour d\u00e9terminer de nouvelles cibles th\u00e9rapeutiques, \u00e9valuer les m\u00e9dicaments candidats et identifier des biomarqueurs dans la prise en charge de pathologies impliquant le microbiote.<\/p>\n<p>Les th\u00e9rapies issues d\u2019un \u00e9cosyst\u00e8me microbien (Microbiome Ecosystem Therapies) d\u00e9velopp\u00e9es par MaaT Pharma peuvent \u00eatre administr\u00e9es par lavement ou encapsul\u00e9e pour une administration orale. Elles sont toutes produites dans le cadre tr\u00e8s standardis\u00e9 d\u2019une fabrication et de contr\u00f4les qualit\u00e9 cGMP afin de garantir en toute s\u00e9curit\u00e9 l\u2019acc\u00e8s \u00e0 la diversit\u00e9 et la richesse du microbiome. MaaT Pharma b\u00e9n\u00e9ficie de l\u2019engagement de scientifiques de renomm\u00e9e mondiale et de relations \u00e9tablies avec les instances r\u00e9glementaires pour \u00eatre le fer de lance des b\u00e9n\u00e9fices th\u00e9rapeutiques de la modulation du microbiote des patients et de son int\u00e9gration dans la pratique clinique.[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]MaaT Pharma est cot\u00e9e sur Euronext Paris (Code mn\u00e9monique\u00a0: MAAT).<\/p>\n<p>Pour plus d\u2019informations\u00a0: <a href=\"https:\/\/maat.swebwp.oci.eu\/fr\">www.maatpharma.com<\/a>\/fr[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][image_with_animation image_url=\u00a0\u00bb5740&Prime; animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong>Avertissement<\/strong><\/p>\n<p>Ce communiqu\u00e9 ne peut \u00eatre distribu\u00e9 directement ou indirectement aux Etats-Unis d\u2019Am\u00e9rique, au Canada, en Australie, au Japon ou en Afrique du Sud.<\/p>\n<p>La diffusion de ce document peut, dans certains pays, faire l\u2019objet d\u2019une r\u00e8glementation sp\u00e9cifique ou constituer une violation des dispositions l\u00e9gales en vigueur. Les personnes en possession du pr\u00e9sent document doivent s\u2019informer des \u00e9ventuelles restrictions locales et s\u2019y conformer. Les informations contenues dans le pr\u00e9sent communiqu\u00e9 ne constituent pas une offre de valeurs mobili\u00e8res aux Etats-Unis d\u2019Am\u00e9rique, au Canada, en Australie, au Japon ou en Afrique du Sud.<\/p>\n<p>Aucune communication, ni aucune information relative \u00e0 l\u2019\u00e9mission, l&rsquo;offre et le placement par la Soci\u00e9t\u00e9 de ses actions (les \u00ab <strong>Actions<\/strong> \u00bb) ne peut \u00eatre diffus\u00e9e au public dans un pays dans lequel une obligation d\u2019enregistrement ou d\u2019approbation est requise. Aucune d\u00e9marche n\u2019a \u00e9t\u00e9 entreprise (ni ne sera entreprise) en dehors de France, dans un quelconque pays dans lequel de telles d\u00e9marches seraient requises. L\u2019\u00e9mission ou la souscription des Actions peuvent faire l\u2019objet dans certains pays de restrictions l\u00e9gales ou r\u00e9glementaires sp\u00e9cifiques. La Soci\u00e9t\u00e9 n\u2019assume aucune responsabilit\u00e9 au titre d\u2019une violation par une quelconque personne de ces restrictions.<\/p>\n<p>Le pr\u00e9sent communiqu\u00e9 ne constitue pas un prospectus au sens du R\u00e8glement (UE) 2017\/1129 du Parlement europ\u00e9en et du Conseil du 14 juin 2017, tel que modifi\u00e9 (le \u00ab <strong>R\u00e8glement Prospectus<\/strong> \u00bb).<\/p>\n<p>Les pr\u00e9sentes informations ne contiennent aucune sollicitation de sommes d\u2019argent, de valeurs mobili\u00e8res ni d\u2019aucune autre contrepartie et, dans le cas o\u00f9 une contrepartie serait envoy\u00e9e en r\u00e9ponse aux informations contenues dans les pr\u00e9sentes, elle ne serait pas accept\u00e9e.<\/p>\n<p>Pour les Etats-Unis et certains autres pays :<\/p>\n<p>Le pr\u00e9sent communiqu\u00e9 et les informations qu\u2019il contient, ne constituent ni une offre de vente ou de souscription, ni la sollicitation d\u2019un ordre d\u2019achat ou de souscription, des actions de la Soci\u00e9t\u00e9 en Australie, au Canada, au Japon, aux Etats-Unis d\u2019Am\u00e9rique, en Afrique du Sud, ni dans un quelconque pays. Les actions de la Soci\u00e9t\u00e9 ne pourront \u00eatre offertes ou vendues aux Etats-Unis d\u2019Am\u00e9rique en l\u2019absence d\u2019enregistrement ou de dispense d\u2019enregistrement au titre du US Securities Act de 1933, tel que modifi\u00e9. Sous r\u00e9serve de certaines exceptions, les actions de la Soci\u00e9t\u00e9 ne pourront \u00eatre offertes ou vendues en Australie, au Canada, au Japon, en Afrique du Sud \u00e0 tout r\u00e9sident ou citoyen d\u2019Australie, du Canada, du Japon ou d\u2019Afrique du Sud. L\u2019offre et la vente des actions de la Soci\u00e9t\u00e9 n\u2019ont pas fait l\u2019objet et ne feront pas l\u2019objet d\u2019un enregistrement au titre du US Securities Act de 1933, tel que modifi\u00e9, ni au titre de toute r\u00e9glementation applicable en Australie, au Canada, au Japon ou en Afrique du Sud. Il n\u2019y aura pas d\u2019enregistrement de tout ou partie de l\u2019offre mentionn\u00e9e dans le pr\u00e9sent communiqu\u00e9 aux \u00c9tats-Unis d\u2019Am\u00e9rique ni de r\u00e9alisation d\u2019une quelconque offre au public portant sur les actions de la Soci\u00e9t\u00e9 aux Etats-Unis d\u2019Am\u00e9rique.<\/p>\n<p>Pour l\u2019Espace Economique Europ\u00e9en :<\/p>\n<p>S\u2019agissant des \u00c9tats membres de l\u2019Espace Economique Europ\u00e9en autres que la France (les \u00ab <strong>\u00c9tats membres<\/strong> \u00bb), aucune action n\u2019a \u00e9t\u00e9 entreprise et ne sera entreprise \u00e0 l\u2019effet de permettre une offre au public des titres rendant n\u00e9cessaire la publication d\u2019un prospectus dans l\u2019un ou l\u2019autre des \u00c9tats membres. En cons\u00e9quence, les Actions ne peuvent \u00eatre offertes et ne seront offertes dans les \u00c9tats membres (i) qu&rsquo;au profit d&rsquo;investisseurs qualifi\u00e9s au sens du R\u00e8glement Prospectus ou (ii) conform\u00e9ment aux autres d\u00e9rogations pr\u00e9vues par l\u2019article 1(4) du R\u00e8glement Prospectus.<\/p>\n<p>Pour les besoins du pr\u00e9sent paragraphe, la notion d\u2019\u00ab offre au public d\u2019Actions \u00bb dans chacun des \u00c9tats membres se d\u00e9finit comme toute communication adress\u00e9e sous quelque forme et par quelque moyen que ce soit \u00e0 des personnes et pr\u00e9sentant une information suffisante sur les conditions de l\u2019offre et sur les Actions \u00e0 offrir, de mani\u00e8re \u00e0 mettre un investisseur en mesure de d\u00e9cider d\u2019acheter ou souscrire ces Actions.<\/p>\n<p>Cette restriction de placement s\u2019ajoute aux autres restrictions de placement applicables dans les \u00c9tats membres.<\/p>\n<p>Le pr\u00e9sent communiqu\u00e9 est une communication \u00e0 caract\u00e8re promotionnel et non un prospectus au sens du R\u00e8glement (UE) 2017\/1129 du Parlement europ\u00e9en et du Conseil europ\u00e9en du 14 juin 2017, concernant le prospectus \u00e0 publier en cas d\u2019offre au public de valeurs mobili\u00e8res ou en vue de l\u2019admission de valeurs mobili\u00e8res \u00e0 la n\u00e9gociation sur un march\u00e9 r\u00e9glement\u00e9, et abrogeant la directive 2003\/71\/CE, tel que modifi\u00e9 (le \u00ab <strong>R\u00e8glement Prospectus<\/strong> \u00bb). Toute d\u00e9cision d\u2019acheter ou de souscrire des actions dans le cadre de l\u2019Offre mentionn\u00e9e dans le pr\u00e9sent communiqu\u00e9 ne devra \u00eatre effectu\u00e9e que sur la seule base de toutes les informations contenues dans le prospectus approuv\u00e9 par l\u2019Autorit\u00e9 des march\u00e9s financiers (l\u2019\u00ab <strong>AMF <\/strong>\u00bb) le 14 octobre 2021 sous le num\u00e9ro 21-445 (le \u00ab <strong>Prospectus <\/strong>\u00bb) compos\u00e9 d\u2019un Document d\u2019Enregistrement enregistr\u00e9 par l\u2019AMF le 1 octobre 2021 sous le num\u00e9ro I.21-057 et le suppl\u00e9ment au Document d&rsquo;Enregistrement approuv\u00e9 par l&rsquo;AMF le 14 octobre 2021 sous le num\u00e9ro I.21-061 (le \u00ab <strong>Document d\u2019Enregistrement <\/strong>\u00bb), d\u2019une note d\u2019op\u00e9ration (la \u00ab <strong>Note d\u2019Op\u00e9ration <\/strong>\u00bb) et d\u2019un r\u00e9sum\u00e9 en fran\u00e7ais, et publi\u00e9 par la Soci\u00e9t\u00e9 dans le cadre de l\u2019offre au public de ses titres, afin de comprendre parfaitement les risques et profits potentiels li\u00e9s \u00e0 la d\u00e9cision d\u2019investir dans les valeurs mobili\u00e8res. Les investisseurs potentiels doivent \u00eatre en mesure de supporter le risque \u00e9conomique d\u2019un investissement dans les titres de la Soci\u00e9t\u00e9 et doivent \u00eatre capables de supporter une perte partielle ou totale de leur investissement. L\u2019approbation du Prospectus par l\u2019AMF ne doit pas \u00eatre comprise comme une approbation des titres offerts.<\/p>\n<p>Pour le Royaume-Uni :<\/p>\n<p>Au Royaume-Uni, le pr\u00e9sent document ne constitue pas un prospectus approuv\u00e9 au sens de l\u2019article 85 du Financial Services and Markets Act 2000 tel qu\u2019amend\u00e9 (le \u00ab <strong>FSMA<\/strong> \u00bb). Il n\u2019a pas \u00e9t\u00e9 pr\u00e9par\u00e9 conform\u00e9ment aux Prospectus Rules \u00e9mises par le UK Financial Conduct Authority (le \u00ab <strong>FCA<\/strong> \u00bb) en application de l\u2019article 73A du FSMA et n\u2019a pas \u00e9t\u00e9 approuv\u00e9 ni d\u00e9pos\u00e9 aupr\u00e8s du FCA ou de toute autre autorit\u00e9 comp\u00e9tente. Les actions nouvelles ou existantes de la Soci\u00e9t\u00e9 ne peuvent \u00eatre offertes ou vendues au public au Royaume-Uni, sauf dans les hypoth\u00e8ses dans lesquelles il serait conforme \u00e0 la loi de le faire sans mise \u00e0 la disposition du public d\u2019un prospectus approuv\u00e9 (au sens de l\u2019article 85 du FSMA) avant que l\u2019offre ne soit r\u00e9alis\u00e9e.<\/p>\n<p>Le pr\u00e9sent communiqu\u00e9 et les informations qu\u2019il contient s\u2019adressent et sont destin\u00e9s uniquement aux personnes situ\u00e9es (x) en dehors du Royaume-Uni ou (y) au Royaume-Uni, qui sont des \u00ab investisseurs qualifi\u00e9s \u00bb (tel que ce terme est d\u00e9fini dans le R\u00e8glement Prospectus qui fait partie du droit interne du Royaume-Uni en application du European Union (Withdrawal) Act 2018) et (i) qui sont des professionnels en mati\u00e8re d\u2019investissements (\u00ab investment professionals \u00bb) au sens de l\u2019article 19(5) du Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, tel que modifi\u00e9 (le \u00ab <strong>Financial Promotion Order<\/strong> \u00bb), (ii) qui sont vis\u00e9es \u00e0 l\u2019article 49(2) (a) \u00e0 (d) du Financial Promotion Order (\u00ab high net worth companies, unincorporated associations etc. \u00bb) ou (iii) sont des personnes auxquelles une invitation ou une incitation \u00e0 participer \u00e0 une activit\u00e9 d\u2019investissement (au sens de l\u2019article 21 du Financial Services and Markets Act 2000) peut \u00eatre l\u00e9galement communiqu\u00e9e ou transmise (les personnes mentionn\u00e9es aux paragraphes (y)(i), (y)(ii) et (y)(iii) \u00e9tant ensemble d\u00e9nomm\u00e9es, les \u00ab Personnes Habilit\u00e9es \u00bb). Toute invitation, offre ou accord en vue de la souscription ou l\u2019achat de titres financiers objet du pr\u00e9sent communiqu\u00e9 est uniquement accessible aux Personnes Habilit\u00e9es et ne peut \u00eatre r\u00e9alis\u00e9(e) que par les Personnes Habilit\u00e9es. Ce communiqu\u00e9 s\u2019adresse uniquement aux Personnes Habilit\u00e9es et ne peut \u00eatre utilis\u00e9 par toute personne autre qu\u2019une Personne Habilit\u00e9e.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Pour la France <\/strong>:<\/p>\n<p>Des exemplaires du Prospectus sont disponibles, sans frais, aupr\u00e8s de la Soci\u00e9t\u00e9, (adresse du si\u00e8ge social : 70 avenue Tony Garner, Lyon 69007, t\u00e9l. : 04 28 29 14 00) ainsi que, sous r\u00e9serve des limitations habituelles, sur les sites internet de la Soci\u00e9t\u00e9 (www.maatpharma.com) et de l\u2019AMF (www.amf-france.org). L\u2019attention du public est attir\u00e9e sur les facteurs de risques figurant dans le Prospectus et en particulier sur mention des risques les plus importants qui peut \u00eatre exig\u00e9e par l\u2019AMF.<\/p>\n<p>Conform\u00e9ment aux exigences en mati\u00e8re de gouvernance des produits pr\u00e9vues par : (a) la Directive 2014\/65\/UE concernant les march\u00e9s d&rsquo;instruments financiers, telle que modifi\u00e9e (\u00ab <strong>MiFID II <\/strong>\u00bb) ; (b) les articles 9 et 10 de la directive d\u00e9l\u00e9gu\u00e9e (UE) 2017\/593 de la Commission compl\u00e9tant la directive MiFID II ; et (c) des mesures de transposition locales (ensemble, les \u00ab<strong>Exigences en mati\u00e8re de gouvernance<\/strong>\u00bb), et d\u00e9clinant toute responsabilit\u00e9, d\u00e9coulant de d\u00e9lit, contrat ou autre, que tout \u00ab producteur \u00bb (au sens des Exigences en mati\u00e8re de gouvernance) pourrait avoir \u00e0 cet \u00e9gard, les actions offertes dans le cadre de l\u2019offre (les \u00ab <strong>Actions Offertes <\/strong>\u00bb) ont \u00e9t\u00e9 soumises \u00e0 un processus d&rsquo;approbation \u00e0 l\u2019issue duquel les Actions Offertes ont \u00e9t\u00e9 d\u00e9termin\u00e9es comme : (i) compatibles avec un march\u00e9 cible final d&rsquo;investisseurs de d\u00e9tail et d&rsquo;investisseurs remplissant les crit\u00e8res des clients professionnels et des contreparties \u00e9ligibles, tels que d\u00e9finis dans la directive MiFID II ; et (ii) \u00e9ligibles \u00e0 la distribution par tous les canaux de distribution, tel qu\u2019autoris\u00e9 par la directive MiFID II (l&rsquo;\u00ab <strong>Evaluation du march\u00e9 cible <\/strong>\u00bb). Nonobstant l&rsquo;Evaluation du march\u00e9 cible, les distributeurs doivent noter que : le prix des Actions Offertes peut diminuer et les investisseurs peuvent perdre tout ou partie de leur investissement ; les Actions Offertes ne garantissent aucun revenu ou protection du capital ; et un investissement dans les Actions Offertes n&rsquo;est appropri\u00e9 que pour les investisseurs qui n&rsquo;ont pas besoin d&rsquo;un revenu garanti ou de protection du capital, qui (seuls ou en collaboration avec un conseiller financier ou autre conseil) sont capables d&rsquo;\u00e9valuer le bien-fond\u00e9 et les risques d&rsquo;un tel investissement et qui disposent de ressources suffisantes pour pouvoir supporter les pertes qui pourraient en r\u00e9sulter.<\/p>\n<p>L&rsquo;Evaluation du march\u00e9 cible est sans pr\u00e9judice des exigences de restrictions de vente contractuelles, l\u00e9gales ou r\u00e9glementaires applicables \u00e0 l\u2019Offre.<\/p>\n<p>A toutes fins utiles, l&rsquo;Evaluation du March\u00e9 Cible ne constitue pas : (a) une \u00e9valuation pour un client donn\u00e9 de la pertinence ou de l&rsquo;ad\u00e9quation aux fins de la directive MiFID II ; ou (b) une recommandation \u00e0 tout investisseur ou groupe d&rsquo;investisseurs d&rsquo;investir, d&rsquo;acheter ou de prendre toute autre mesure \u00e0 l&rsquo;\u00e9gard des Actions Offertes.<\/p>\n<p>Chaque distributeur est responsable de r\u00e9aliser sa propre \u00e9valuation du march\u00e9 cible applicable aux Actions Offertes et de d\u00e9terminer les canaux de distribution appropri\u00e9s.<\/p>\n<p>Pour \u00e9viter toute ambig\u00fcit\u00e9, m\u00eame si le march\u00e9 cible inclut les investisseurs de d\u00e9tail, les producteurs et les distributeurs ont d\u00e9cid\u00e9 qu&rsquo;ils fourniront uniquement des investisseurs pour les Actions Offertes r\u00e9pondant aux crit\u00e8res d&rsquo;\u00e9ligibilit\u00e9 des contreparties \u00e9ligibles et des clients professionnels.[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bbsmall\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbT\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/211203_CP-MaaT-Pharma_Exercice-Option-Surallocation_FR-Final.pdf\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[49],"class_list":{"0":"post-5756","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-49"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-06T06:41:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T13:54:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac\",\"datePublished\":\"2021-12-06T06:41:19+00:00\",\"dateModified\":\"2023-09-25T13:54:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\"},\"wordCount\":4193,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\",\"name\":\"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2021-12-06T06:41:19+00:00\",\"dateModified\":\"2023-09-25T13:54:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/","og_site_name":"MaaT Pharma","article_published_time":"2021-12-06T06:41:19+00:00","article_modified_time":"2023-09-25T13:54:24+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac","datePublished":"2021-12-06T06:41:19+00:00","dateModified":"2023-09-25T13:54:24+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/"},"wordCount":4193,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/","url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/","name":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2021-12-06T06:41:19+00:00","dateModified":"2023-09-25T13:54:24+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-announces-the-partial-exercise-of-the-over-allotment-option-and-the-total-size-of-the-offering-at-approximately-e-35-7m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma annonce l\u2019exercice partiel de l\u2019option de surallocation et le montant d\u00e9finitif de l\u2019offre port\u00e9 \u00e0 environ 35,7 M\u20ac"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/5756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=5756"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/5756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=5756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=5756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=5756"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=5756"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=5756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}